cenobamate (Xcopri)
Jump to navigation
Jump to search
Indications
- partial-onset seizures in adults
Dosage
Tabs: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg
Adverse effects
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) when cenobamate rapidly titrated
- shortening of the QT interval
- suicidal ideation
- somnolence, dizziness, fatigue, diplopia, headache.
More general terms
References
- ↑ FDA News Release. Nov 21, 2019 FDA approves new treatment for adults with partial-onset seizures. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-partial-onset-seizures
- ↑ FDA Approves XCOPRI(cenobamate tablets), an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co.,Ltd.,andU.S. Subsidiary SK Life Science, Inc https://www.sklifescienceinc.com/pdf/FDA_Approves_XCOPRI_(cenobamate_tablets)_an_Anti-Epileptic_Drug_(AED)_from_SK_Biopharmaceuticals_Co._Ltd._and_U.S._Subsidiary_SK_Life_Science_Inc.pdf